AssayIndex

CPC-2607-L3107

Tirzepatide · 60 mg declared · Chinese Peptide Company Co., Ltd. · manufactured 23 Jul 2026

CHARACTERISED
Lot code
CPC-2607-L3107
Supplier
CPC — Chinese Peptide Company Co., Ltd.
Compound
Tirzepatide
Compound class
Incretin analogues and co-agonists
Declared label claim
60mg
Manufacture date
23 Jul 2026
Index quarter
2026-Q3
Independent assays
13
Laboratories involved
VendorInvestigate, PeptideMeter, Janoshik, Medutest, Kestrel
Provenance mix
Buyer-sourced ×8 · Supplier-supplied ×5
Section 1

Reproducibility across independent tests

Every report below is an observation of the same physical material. What they disagree about is measurement; what they agree about is the lot. The size of the disagreement is compared against what the contributing laboratories' own repeatability figures predict.

Independent assays 13
Median purity 97.06% n=13
Spread (max − min) 1.92pp n=13
Standard deviation 0.525pp n=13
95.796.597.298.098.799.5100.2This lot (CPC-2607-L3107)This lot (CPC-2607-L3107): Q1 96.47, median 97.06, Q3 97.17, n=13n=13All TirzepatideAll Tirzepatide: Q1 97.99, median 98.54, Q3 98.98, n=706outlier 96.03outlier 96.21outlier 96.46outlier 96.47n=706 Purity (% area)
Figure 1. This lot's independent purity results against the whole Tirzepatide record set in the index. The vertical line is the index acceptance specification for the incretin analogues and co-agonists class, 97.0 % area. A narrow box on the top row against a wide box on the bottom row is the ideal reading: it means the disagreement between lots is much larger than the disagreement within this one.
Section 2

Member reports 13

Every report the index holds on this lot. Each is a page carrying its own chromatogram, mass spectrum, mass balance, provenance and caveats.

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-043440CPC-2607-L3107VendorInvestigate2026-Q396.035.46105.8Buyer-sourced0FAIL
AX-2026-043441CPC-2607-L3107PeptideMeter2026-Q397.954.10100.6Supplier-supplied0PASS
AX-2026-043442CPC-2607-L3107Janoshik2026-Q397.294.73106.2Buyer-sourced0PASS
AX-2026-043443CPC-2607-L3107Medutest2026-Q396.544.8099.9Buyer-sourced0FAIL
AX-2026-043444CPC-2607-L3107Medutest2026-Q397.174.75107.2Supplier-supplied1MARGINAL
AX-2026-043445CPC-2607-L3107PeptideMeter2026-Q397.164.43102.8Supplier-supplied0PASS
AX-2026-043446CPC-2607-L3107Janoshik2026-Q396.855.40Buyer-sourced0FAIL
AX-2026-043447CPC-2607-L3107Kestrel2026-Q397.064.51Buyer-sourced0PASS
AX-2026-043448CPC-2607-L3107Medutest2026-Q397.215.42107.0Supplier-supplied0PASS
AX-2026-043449CPC-2607-L3107PeptideMeter2026-Q397.124.7195.0Supplier-supplied0PASS
AX-2026-043450CPC-2607-L3107Medutest2026-Q396.215.17Buyer-sourced0FAIL
AX-2026-043451CPC-2607-L3107Janoshik2026-Q396.465.38Buyer-sourced0FAIL
AX-2026-043452CPC-2607-L3107Janoshik2026-Q396.475.46Buyer-sourced0FAIL
Section 3

By laboratory

Where more than one laboratory assayed this lot, the difference between them is a paired observation of their relative bias — the same material, the same time window, different instruments. Those pairs are what the index's bias estimates are built from.

LaboratoryReportsPurity results (% area)MedianGradientPublished bias (pp)Bias-adjusted
VendorInvestigate196.0396.0332min-0.1196.14
PeptideMeter397.95, 97.16, 97.1297.1628min-0.0597.21
Janoshik497.29, 96.85, 96.46, 96.4796.6630min+0.0096.66
Medutest496.54, 97.17, 97.21, 96.2196.8625min+0.0896.78
Kestrel197.0697.0615min+0.2496.82

This lot contributes 10 paired comparisons to the inter-lab analysis.

Section 4

The supplier's certificate for this lot

One number the supplier wrote, beside the median of the numbers other people measured on the same physical material. That comparison is only available because the index groups by lot.

FigureSupplier COAThis reportIndex note
Purity (% area)96.6796.03divergence -0.39 pp vs batch median
Total impurities (% area)not stated3.97
Largest single impurity (% area)not stated2.65
Water (%)not stated5.46
Counter-ion (%)not stated6.06
Peptide content (%w/w)not stated87.67
Endotoxin (EU/mg)not statednot determined
Method stated on certificateYEScolumn, gradient and wavelength given
Section 5

Impurity fingerprint

The named impurities reported across this lot's assays, with how consistently each was seen. A fingerprint is what allows two lot numbers held by different companies to be identified as one bulk.

Named impurityReported inMedian % areaRange
[D-Aib13]-diastereomer13 / 131.810.02–2.65
des-Gly deletion (−57 Da)13 / 130.110.04–0.16
Met(O) sulfoxide (+16 Da)13 / 130.040.02–1.66
C20 diacid mono-amide13 / 130.030.02–0.40
tirzepatide dimer7 / 130.670.58–0.85
truncated (3-39)7 / 130.190.17–0.24
trifluoroacetyl adduct (+96 Da)6 / 131.040.74–1.27
des-Aib2 analogue6 / 130.080.06–0.10
Section 7

What this rollup does not establish